• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Consumer Cyclical·COUR
Held by 2 Gurus
Share

Coursera, Inc. Stocks

$ 5.31Last Updated 31.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

$ 975.00M

$ 5.31
Key Takeaways

Risk factor

Strong trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

In Guru Portfolios

Bob Prince, Greg Jensen, Karen Karniol-Tambour

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

Bridgewater Associates

Kenneth Griffin

Portfolio Weight (%)

0.0%

Change

+0.00%

Fund

CITADEL ADVISORS LLC

Manager
Fund
Portfolio Weight (%)
Change
Bob Prince, Greg Jensen, Karen Karniol-TambourBridgewater Associates0.0%+0.00%
Kenneth GriffinCITADEL ADVISORS LLC0.0%+0.00%

Latest news

24.04.2026 15:40

Morning in New York: Intel and SAP reports will set the tone for trading

02.04.2026 14:38

Insider Monkey: 10 small-cap consumer staples names under $30

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Coursera, Inc. operates an online learning platform that provides education and skills training in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates through Consumer and Enterprise segments. The company offers guided projects, courses, and specializations; online bachelor’s and master’s degrees; postgraduate diplomas; and certificates for entry-level professional, non-entry level professional, university, and MasterTrack programs in the domains of business, computer science, technology, and data science through Coursera.org for Individuals, Coursera Plus, Coursera for Enterprise, Coursera for Business, Coursera for Campus, and Coursera for Government. It offers its products to individuals, businesses, institutions, employers, colleges and universities, organizations, and governments. The company was formerly known as Dkandu, Inc. and changed its name to Coursera, Inc. in April 2012. Coursera, Inc. was incorporated in 2011 and is headquartered in Mountain View, California.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, ove

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of COUR is 7.91 and suggests 49% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

03.08.2026 15:20

Warsh suggested that the Fed might reduce the number of meetings on interest rates

03.08.2026 14:41

Shares of a small-cap biotech company soared 107%. Its melanoma drug is close to approval.

03.08.2026 13:25

Morgan Stanley Expects Korean Stocks to Soar 44% After Their Worst Month Since 2008

03.08.2026 12:16

Concrete or a Presentation: How to Profit from Kazakhstan’s Investments in AI

03.08.2026 11:43

SpaceX's Earnings Report, the Job Market, and Big Pharma: What Investors Can Expect This Week

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026